Hypomethylating agents are the current therapy backbone for MDS and AML relapsing after allogeneic hematopoietic stem cell transplantation. [PDF]
Kobbe G +7 more
europepmc +1 more source
Alantolactone inhibits T-cell lymphoma progression by suppressing CD47 expression via the PI3K/AKT and ERK signaling pathways. [PDF]
Li X +8 more
europepmc +1 more source
Myelodysplastic Syndromes: 2026 Update on Diagnosis, Risk-Stratification and Management. [PDF]
Garcia-Manero G.
europepmc +1 more source
A53-Adapted Decitabine-Containing R-CHOP in Newly Diagnosed Diffuse Large B-Cell Lymphoma Defined by LymphGen: Preliminary Results of a Prospective Proof-of-Concept Study. [PDF]
Mingalimov M +22 more
europepmc +1 more source
TIM3 Blockade with Hypomethylating Therapy Restores NK Cell and Cytotoxic CD4+ T-cell Activity in Patients with AML or MDS. [PDF]
Huuhtanen J +22 more
europepmc +1 more source
Increasing TET Expression and 5-Hydroxymethylcytosine Formation by a Carbocyclic 5-Aza-2'-deoxy-cytidine Antimetabolite. [PDF]
Däther M +17 more
europepmc +1 more source
Low-dose decitabine combined with camrelizumab for refractory/relapsed mycosis fungoides/Sézary syndrome: a retrospective exploratory study. [PDF]
Meng S +6 more
europepmc +1 more source
Structural and cellular insights into DCTPP1 antagonists and their synergistic action with DNMT inhibitors. [PDF]
Hauk G +4 more
europepmc +1 more source
Treatment of Acute Myeloid Leukemia in the Elderly. [PDF]
Vadnagara H +5 more
europepmc +1 more source
Age-Stratified Conditioning Regimens for Allogeneic Hematopoietic Stem Cell Transplantation in Patients With Myelodysplastic Syndromes: A Comprehensive Review. [PDF]
Wu N +8 more
europepmc +1 more source

